Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

An integrated disease-specific graded prognostic assessment scale for melanoma: contributions of KPS, CITV, number of metastases, and BRAF mutation status

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Male hormone-interfering drugs and meningioma development

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. TERT promoter mutations in primary and secondary WHO grade III meningioma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The Ki-67 Proliferation Index as a Marker of Time to Recurrence in Intracranial Meningioma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Preoperative antibiotic prophylaxis regimen in brain tumour surgery in Sweden: a quasi-experimental study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Return to work following diagnosis of low-grade glioma: A nationwide matched cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Human RTEL1 associates with Poldip3 to facilitate responses to replication stress and R-loop resolution

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Manmeet Ahluwalia
  • Mir A Ali
  • Rushikesh S Joshi
  • Eun Suk Park
  • Birra Taha
  • Ian McCutcheon
  • Veronica Chiang
  • Angela Hong
  • Georges Sinclair
  • Jiri Bartek
  • Clark C Chen
View graph of relations

Background: Stereotactic radiosurgery (SRS) remains a mainstay therapy in the treatment of melanoma brain metastases (BM). While prognostic scales have been developed for melanoma patients who underwent SRS treatment for BM, the pertinence of these scales in the context of molecularly targeted therapies remains unclear.

Methods: Through a multi-institutional collaboration, we collated the survival patterns of 331 melanoma BM patients with known BRAF mutation status treated with SRS. We established a prognostic scale that was validated in an independent cohort of 174 patients. All patients with BRAF mutations in this series were treated with BRAF inhibitors. Prognostic utility was assessed using Net Reclassification Index (NRI > 0) and integrated discrimination improvement (IDI) metrics.

Results: In a multivariate Cox proportional hazards model, BRAF mutation status, KPS, number of metastases, and cumulative intracranial tumor volume (CITV) independently contributed to survival prognostication for melanoma patients with SRS-treated BM (P < .05 for all variables). These variables were incorporated into a prognostic scale using the disease-specific graded prognostic assessment (ds-GPA) framework. This integrated melanoma ds-GPA scale was validated in 2 independent cohorts collated through a multi-institutional collaboration. In terms of order of prognostic importance, BRAF mutation status exerted the greatest influence on survival, while KPS, the number of metastases, and CITV exhibited comparable, lesser impacts.

Conclusions: Optimal survival prognostication for SRS-treated patients with melanoma BM requires an integrated assessment of patient characteristics (KPS), tumor characteristics (CITV and number of metastases), and the mutational profile of the melanoma (BRAF mutation status).

Original languageEnglish
JournalNeuro-Oncology Advances
Volume3
Issue number1
Pages (from-to)vdaa152
ISSN2632-2498
DOIs
Publication statusPublished - 29 Jan 2021

ID: 64686487